<DOC>
	<DOCNO>NCT03105219</DOCNO>
	<brief_summary>To explore efficacy Ivabradine treatment microalbuminuria patient type 2 diabetes coronary heart disease .</brief_summary>
	<brief_title>IvaBradinE Treat MicroalbumiNuria Patients With Type 2 Diabetes Coronary Heart Disease</brief_title>
	<detailed_description>This multi-center , randomize , open-label , investigator-initiated study parallel design . Patients type 2 diabetes coronary heart disease microalbuminuric [ urinary albumin excretion ( UAE ) : 30-500 mg/day ] , randomize informed consent , 1:1 ratio follow treatment group : Group Α : Ivabradine 5mg twice day ( day 0 ) , heart rate evaluate day 14 28 repeatedly , target value heart rate 50-60bpm , large dosage 7.5mg twice day . Group Β : Placebo . Urinary albumin excretion ( UAE ) assessment perform randomization ( Day 0 ) , 28-day randomization ( Day 28 ) , 90-day randomization ( Day 28 ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>1 . Type 2 diabetes coronary heart disease ; 2 . Urinary albumin excretion : 30500mg/24h ; 3 . Sinus rhythm , rest heart rate ≥ 70bpm ; 1 . Renal dysfunction define eGFR &lt; 30ml/min/1.73m^2 ; 2 . Atrial flutter , atrial fibrillation ; 3 . Resting heart rate &lt; 70bpm ; 4 . Combined nondihydropyridine CCB ; 5 . UAE &lt; 30mg/24h , &gt; 500mg/24h ; 6 . Acute heart failure ; 7 . Low blood pressure ( BP &lt; 90/50mmHg ) ; 8 . Acute myocardial infarction ( &lt; 14 day ) ;</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>